{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:02:00Z","timestamp":1792314120018,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11845-022-03153-0","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T06:02:36Z","timestamp":1663394556000},"page":"1657-1660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis"],"prefix":"10.1007","volume":"192","author":[{"given":"John P.","family":"ONeill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal S","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh P.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5994-6023","authenticated-orcid":false,"given":"P. Aiden","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"issue":"4","key":"3153_CR1","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/hep.30148","volume":"69","author":"PY Boelle","year":"2019","unstructured":"Boelle PY, Debray D, Guillot L et al (2019) Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology 69(4):1648\u20131656","journal-title":"Hepatology"},{"issue":"10059","key":"3153_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS (2016) Cystic fibrosis. Lancet 388(10059):2519\u20132531","journal-title":"Lancet"},{"issue":"4","key":"3153_CR3","doi-asserted-by":"publisher","first-page":"e0212779","DOI":"10.1371\/journal.pone.0212779","volume":"14","author":"MB Toledano","year":"2019","unstructured":"Toledano MB, Mukherjee SK, Howell J et al (2019) The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PLoS ONE 14(4):e0212779","journal-title":"PLoS ONE"},{"issue":"4","key":"3153_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/apt.16749","volume":"55","author":"J Scott","year":"2022","unstructured":"Scott J, Jones AM, Piper Hanley K, Athwal VS (2022) Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 55(4):389\u2013400","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"3153_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/MCP.0000000000000824","volume":"27","author":"VS Athwal","year":"2021","unstructured":"Athwal VS, Scott JA, Fitzpatrick E, Rowland M (2021) Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 27(6):593\u2013599","journal-title":"Curr Opin Pulm Med"},{"issue":"6","key":"3153_CR6","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/hep.1840360613","volume":"36","author":"C Colombo","year":"2002","unstructured":"Colombo C, Battezzati PM, Crosignani A et al (2002) Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 36(6):1374\u20131382","journal-title":"Hepatology"},{"issue":"10","key":"3153_CR7","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/lt.24842","volume":"23","author":"S Hillaire","year":"2017","unstructured":"Hillaire S, Cazals-Hatem D, Bruno O et al (2017) Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl 23(10):1342\u20131347","journal-title":"Liver Transpl"},{"issue":"3","key":"3153_CR8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/hep.24183","volume":"53","author":"P Witters","year":"2011","unstructured":"Witters P, Libbrecht L, Roskams T et al (2011) Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology 53(3):1064\u20131065","journal-title":"Hepatology"},{"issue":"10","key":"3153_CR9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","volume":"17","author":"H Wu","year":"2019","unstructured":"Wu H, Vu M, Dhingra S et al (2019) Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol 17(10):2134\u20132136","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3153_CR10","doi-asserted-by":"crossref","unstructured":"Cheng K, Ashby D, Smyth RL (2017) Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 9:CD000222","DOI":"10.1002\/14651858.CD000222.pub4"},{"key":"3153_CR11","doi-asserted-by":"crossref","unstructured":"Staufer K (2020) Current treatment options for cystic fibrosis-related liver disease. Int J Mol Sci 21(22)","DOI":"10.3390\/ijms21228586"},{"issue":"5","key":"3153_CR12","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jcf.2017.03.006","volume":"16","author":"P Witters","year":"2017","unstructured":"Witters P, Libbrecht L, Roskams T et al (2017) Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cyst Fibros 16(5):e11\u2013e13","journal-title":"J Cyst Fibros"},{"issue":"1","key":"3153_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jcf.2014.05.013","volume":"14","author":"M Rowland","year":"2015","unstructured":"Rowland M, Gallagher C, Gallagher CG et al (2015) Outcome in patients with cystic fibrosis liver disease. J Cyst Fibros 14(1):120\u2013126","journal-title":"J Cyst Fibros"},{"key":"3153_CR14","doi-asserted-by":"crossref","unstructured":"Palaniappan SK, Than NN, Thein AW, van Mourik I (2020) Interventions for preventing and managing advanced liver disease in cystic fibrosis. Cochrane Database Syst Rev 3:CD012056","DOI":"10.1002\/14651858.CD012056.pub3"},{"issue":"5","key":"3153_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","volume":"4","author":"A De Gottardi","year":"2019","unstructured":"De Gottardi A, Rautou PE, Schouten J et al (2019) Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol 4(5):399\u2013411","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"3153_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.14740\/gr1376","volume":"14","author":"M Kmeid","year":"2021","unstructured":"Kmeid M, Liu X, Ballentine S, Lee H (2021) Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data. Gastroenterol Res 14(2):49\u201365","journal-title":"Gastroenterol Res"},{"key":"3153_CR17","first-page":"265","volume":"14","author":"IR Wanless","year":"1996","unstructured":"Wanless IR (1996) Noncirrhotic portal hypertension: recent concepts. Prog Liver Dis 14:265\u2013278","journal-title":"Prog Liver Dis"},{"issue":"2","key":"3153_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","volume":"76","author":"J Dana","year":"2022","unstructured":"Dana J, Debray D, Beaufrere A et al (2022) Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 76(2):420\u2013434","journal-title":"J Hepatol"},{"key":"3153_CR19","unstructured":"Abraldes JG, Villanueva C, Aracil C et al (2016) Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150(5):1160\u20131170 e3"},{"issue":"28","key":"3153_CR20","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3748\/wjg.v27.i28.4639","volume":"27","author":"AE Munoz","year":"2021","unstructured":"Munoz AE, Pollarsky FD, Marino M et al (2021) Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy. World J Gastroenterol 27(28):4639\u20134652","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3153_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hep.24014","volume":"53","author":"PJ Lewindon","year":"2011","unstructured":"Lewindon PJ, Shepherd RW, Walsh MJ et al (2011) Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 53(1):193\u2013201","journal-title":"Hepatology"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03153-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03153-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T10:17:55Z","timestamp":1690798675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03153-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3153"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03153-0","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"2 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted retrospectively from data obtained for clinical purposes. Permission was granted by the St Vincent\u2019s University Hospital audit committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}